Roughly speaking, calculation is based on
1- $51M valuation if Albireo pipeline 2- $10M cash infusion by investors of Albireo 3- Negative $5M net cash of Albireo 4- Only $21M to $22M net cash from Biodel (I don't understand why below $30 we have from balance sheet, end of june)
This mix gives 70/30 to Albirep/Biodel
If so, there is def. room for sale of bio pipeline and lawsuit settlement and div that to us prior to closing
This is a fantastic deal to get 30% of Alberio for only $22M. This stock should shoot up, if I am righ |